The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma

Androgen receptor blocking agents have become an established form of therapy for men with disseminated prostate carcinoma. The purpose of this study was to evaluate markers of bone turnover and to measure bone mineral densities (BMD) in men with disseminated prostate carcinoma treated with combined androgen blockade prior to and after 6 months of intermittent cyclic etidronate therapy.

[1]  M. Garnick.  Hormonal therapy in the management of prostate cancer: from Huggins to the present. , 1997, Urology.

[2]  H. Daniell.  Osteoporosis after orchiectomy for prostate cancer. , 1997, The Journal of urology.

[3]  S. Graham,et al.  Bone fractures associated with luteinizing hormone‐releasing hormone agonists used in the treatment of prostate carcinoma , 1997, Cancer.

[4]  G. Hortobagyi,et al.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.

[5]  P. Delmas.  Bisphosphonates in the treatment of bone diseases. , 1996, The New England journal of medicine.

[6]  T. Mukherjee,et al.  A randomized, placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment. , 1996, American journal of obstetrics and gynecology.

[7]  G. Rodan,et al.  Bisphosphonates: mechanisms of action , 1998, Endocrine reviews.

[8]  T. Diamond,et al.  Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. , 1995, The Journal of urology.

[9]  S. Barbagallo,et al.  Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. , 1995, The American journal of medicine.

[10]  D. Mcleod,et al.  Hormonal therapy in the treatment of carcinoma of the prostate , 1995 .

[11]  R. Jilka,et al.  Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. , 1995, The New England journal of medicine.

[12]  S. Manolagas.  Bone marrow, cytokines, and bone remodeling , 1995 .

[13]  J. Sibilia,et al.  Gonadotrophin-releasing hormone agonists induce osteoporosis. , 1994, British journal of rheumatology.

[14]  J. Eisman,et al.  Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study , 1994, BMJ.

[15]  R. Vorreuther.  Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. , 1993, British journal of urology.

[16]  A. Goulding,et al.  Flutamide‐mediated androgen blockade evokes osteopenia in the female rat , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  Y. Weisman,et al.  Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). , 1993, The Journal of clinical endocrinology and metabolism.

[18]  N. Clarke,et al.  The effects of orchidectomy on skeletal metabolism in metastatic prostate cancer. , 1993, Scandinavian journal of urology and nephrology.

[19]  A. Geldof,et al.  Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates. , 1992, The Journal of urology.

[20]  A. Vermeulen,et al.  Editorial : role of the hypothalamo-pituitary function in the hypoandrogenism of healthy aging , 1992 .

[21]  A. Vermeulen,et al.  Role of the hypothalamo-pituitary function in the hypoandrogenism of healthy aging. , 1992, The Journal of clinical endocrinology and metabolism.

[22]  W. Mysiw,et al.  Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. , 1990, The New England journal of medicine.

[23]  M. Kleerekoper,et al.  Osteoporosis in Men: Diagnosis, Pathophysiology, and Prevention , 1990, Medicine.

[24]  E. Orwoll,et al.  The impact of osteophytic and vascular calcifications on vertebral mineral density measurements in men. , 1990, The Journal of clinical endocrinology and metabolism.

[25]  D. Baylink,et al.  Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. , 1989, The Journal of clinical endocrinology and metabolism.

[26]  M. Kleerekoper,et al.  Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. , 1987, The Journal of clinical endocrinology and metabolism.

[27]  J. Kanis,et al.  Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. , 1987, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[28]  H. Genant,et al.  Bone mineral content in early-postmenopausal and postmenopausal osteoporotic women: comparison of measurement methods. , 1986, Radiology.